跳至主要内容
临床试验/EUCTR2008-004122-17-NL
EUCTR2008-004122-17-NL进行中(未招募)1 期

International Study to Predict Optimised Treatment - in DepressioniSPOT-D - iSPOT-D

BRC operations Pty. Ltd.0 个研究点目标入组 2,163 人开始时间: 2008年8月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
2,163

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Meet DSM-IV criteria for primary diagnosis of MDD
  • - HAM-D21 score of >16.
  • Patients and controls
  • -18-65 years age-range (inclusive)
  • - Subjects with Dutch fluency.
  • - Written, informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Presence of suicidal ideations and/or tendencies, bipolar disorder, psychosis or primary eating disorders.
  • - Pregnancy and women of child bearing potential who are not taking a medically
  • accepted form of contraception
  • - Breastfeeding.
  • -Known contra-indication to the use of Escitalopram, Sertraline or Venlafaxine XR as
  • defined in the product package insert for each drug
  • -Use of any antidepressant or CNS drug which can not be washed out prior to
  • participation.
  • -Use of any medication which is known to be contraindicated
  • - Evidence of either hyper or hypo-thyroidism within previous 3 months.

研究者

发起方
BRC operations Pty. Ltd.

相似试验